These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17660022)

  • 1. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
    Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
    Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal effects of anti-angiogenesis therapy: update for the internist.
    Gurevich F; Perazella MA
    Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
    Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
    Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
    Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
    J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
    Izzedine H
    Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrolyte disorders related to EGFR-targeting drugs.
    Izzedine H; Bahleda R; Khayat D; Massard C; Magné N; Spano JP; Soria JC
    Crit Rev Oncol Hematol; 2010 Mar; 73(3):213-9. PubMed ID: 19403315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic-induced hypertension: the molecular basis of signaling network.
    Nagai A; Sado T; Naruse K; Noguchi T; Haruta S; Yoshida S; Tanase Y; Tsunemi T; Kobayashi H
    Gynecol Obstet Invest; 2012; 73(2):89-98. PubMed ID: 22222493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
    Vigneau C; Rioux-Leclercq N
    Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anticancer drugs under pressure].
    Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
    Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional symbiosis between endothelium and epithelial cells in glomeruli.
    Hirschberg R; Wang S; Mitu GM
    Cell Tissue Res; 2008 Feb; 331(2):485-93. PubMed ID: 17999087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis.
    Benter IF; Canatan H; Benboubetra M; Yousif MH; Akhtar S
    Vascul Pharmacol; 2009; 51(2-3):101-9. PubMed ID: 19410658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
    van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
    J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination targeted therapy in advanced renal cell carcinoma.
    Sosman J; Puzanov I
    Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
    Izzedine H; Mangier M; Ory V; Zhang SY; Sendeyo K; Bouachi K; Audard V; Péchoux C; Soria JC; Massard C; Bahleda R; Bourry E; Khayat D; Baumelou A; Lang P; Ollero M; Pawlak A; Sahali D
    Kidney Int; 2014 Feb; 85(2):457-70. PubMed ID: 24067439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
    Eremina V; Quaggin SE
    Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors].
    Rollino C; Beltrame G; Ferro M; Quattrocchio G; Tonda L; Quarello F
    G Ital Nefrol; 2010; 27 Suppl 50():S70-4. PubMed ID: 20922699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.